Shanghai Huaota Biopharmaceutical's HB0034 anti-IL-36R monoclonal antibody injection was granted orphan drug designation by the U.S. FDA for the treatment of generalized pustular psoriasis (GPP).

The 2023 ESMO congress selected Shanghai Junshi Biosciences' phase III trial, EXTENTORCH, on anti-PD-1 monoclonal antibody toripalimab for the LBA.

The GEMSTONE-303 Phase III trial of CStone Pharmaceuticals' sugemalimab was selected for an LBA report at the 2023 ESMO conference.

Recently, Sanofi announced the latest data from the Phase 3 clinical trial named PROTECT for Tzield (teplizumab).

Recently, AstraZeneca announced that the National Medical Products Administration (NMPA) of China has approved C5 complement inhibitor Eculizumab for the treatment of adults.

Recently, UCB announced that the FDA has approved Bimzelx(bimekizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic treatment or phototherapy.

Angany Inc.. has revealed that it has obtained approval from MHRA to carry out the initial clinical trial of its vaccine candidate ANG-101 aimed at combating allergies in humans to cats.

Merck recently proclaimed that the Phase 3 AMBASSADOR study assessing KEYTRUDA, an anti-PD-1 treatment developed by Merck.

In conjunction with Zealand Pharma A/S, Boehringer Ingelheim has initiated three Phase III research investigations for survodutide (also known as BI 456906)

First patient administered by Tenaya Therapeutics in MyPeak-1™ Phase 1b Clinical Trial for TN-201 treatment to address MYBPC3-Associated Hypertrophic Cardiomyopathy.

Oncternal Therapeutics starts administrating the first dose in phase 1/2 trial of ONCT-534, a dual-action AR inhibitor, for metastatic castration-resistant prostate cancer patients.

Janssen applies to the European Medicines Agency, seeking approval for using RYBREVANT (amivantamab) combined with chemotherapy to treat adults initially diagnosed with late-stage Non-Small Cell Lung Cancer with proficient EGFR Exon 20 Insertion Mutations.